B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF).

B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM.

BCMA (B-cell maturation antigen) is a cell surface receptor predominantly expressed in plasma cells and overexpressed in malignant plasma cells. In parallel, the expression of soluble BCMA is found to be elevated in the serum of patients with multiple myeloma (MM) and leukemia.

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or ...

Sep 23, 2023 · Linvoseltamab (REGN5458) and REGN5459 are BCMA x CD3 bispecific antibodies designed to bind to the BCMA present on multiple myeloma cells and the CD3 receptor on T-cells, bridging them together and activating T-cell killing of the cancerous myeloma cells.

Dec 7, 2017 · BCMA expression is seen in many more B cell malignancies than previously recognized, including in a number of aggressive B cell neoplasms such as high grade B-cell lymphomas Burkitt and plasmablastic lymphomas.

BCMA is notably present on both healthy and malignant B cells, and its increased presence in the blood of multiple myeloma patients suggests a link to the disease's progression. Researchers are exploring innovative therapies that leverage BCMA's unique expression pattern.

Mar 11, 2025 · To characterize the terminal maturation of plasma cells, we constructed a BCMA reporter mouse (BCMA:Tom) that exclusively labeled antibody-secreting cells and revealed that BCMA:Tom expression varied by IgH isotype and increased with plasma cell maturity.

BCMA, B cell maturation antigen, is a member of the TNF receptor superfamily. It has been designated TNFRSF17. BCMA is a type III membrane protein containing one extracellular cysteine rich domain. Within the TNFRSF, it shares the highest homology with TACI.

BCMA is a tumor necrosis factor superfamily receptor for the cytokines a proliferation-inducing ligand (APRIL) and B cell–activating factor that promote activation and survival. BCMA is almost exclusively expressed on plasma cells, which are absent or significantly reduced in CVID.